Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dana-Farber Cancer Institute and Lifespan leadership have signed a memorandum of understanding to form a partnership that will advance cancer treatment and expand research. The details will be finalized early next year.
“Over the past six months, our staff members have been meeting to learn more about our respective organizations’ strengths, and to identify priorities for a partnership that will ensure the best cancer care is available for those in our community,” said Timothy Babineau, MD, president and CEO of Lifespan. “We are proud to be building a partnership with one of the leading cancer centers in the United States.”
“We are excited about the possibilities offered by working closely with Lifespan,” said Edward J. Benz, Jr., MD, president and CEO of Dana-Farber. “Our mission is to help develop new and more effective therapies and to ensure that they reach as many people as possible. That can only be done by partnering with selected, high quality collaborators such as Lifespan.”
The partnership will focus on five areas: genomics and precision medicine; clinical trials; value-based care and cancer care delivery innovation; shared care models; and cancer workforce development. As the planning moves forward, the two organizations are already collaborating on a multi-site grant application to the National Human Genome Research Institute (NHGRI) to study the clinical utility of genomics information.
Lifespan’s Comprehensive Cancer Center patients will continue to receive excellent cancer care in Rhode Island, but patients with rare and more complex cancers will benefit from seamless referrals
and coordination of care at Dana-Farber. “The partnership will allow Lifespan to access the outstanding faculty, research resources, and programs of Dana-Farber to benefit patients in Rhode Island,” said Babineau. Aiding in the organizations’ partnership is a common cancer-specific electronic health record system, the Epic Beacon platform, that will facilitate coordination of care, and both organizations will be using the same OnCore clinical trials management system.
“This is an exciting opportunity to create a meaningful and impactful partnership,” said David E. Wazer, MD, director of the Lifespan Comprehensive Cancer Center. “More can be accomplished when strong organizations work together on joint research projects, the development of innovative new treatments, and ensuring access to the best care for our entire community.”
Posted on September 22, 2016
For all inquiries, call 617-632-4090 and ask to speak to a member of the media team. Please direct emails to email@example.com.
New Patient Appointments
For adults: 877-442-3324For children: 888-733-4662